As a clinical trial, targeting IDO with a peptide vaccine elicits long-lasting disease stabilization in lung cancer patients along with reduction of Treg frequency and increased cytotoxicity of CD8+ T cells to kill cancer cells (196). The gene discussed is CD8A; the disease is lung carcinoma.